Glucagon-Like Receptor 1 Agonists and DPP-4 Inhibitors: Potential Therapies for the Treatment of Stroke
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Glucagon-Like Receptor 1 Agonists and DPP-4 Inhibitors: Potential Therapies for the Treatment of Stroke
Authors
Keywords
-
Journal
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
Volume 35, Issue 5, Pages 718-723
Publisher
SAGE Publications
Online
2015-02-11
DOI
10.1038/jcbfm.2015.17
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study
- (2014) Seoyoung C. Kim et al. ACTA DIABETOLOGICA
- Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors
- (2014) B. Omar et al. DIABETES
- Activation of Spinal Glucagon-Like Peptide-1 Receptors Specifically Suppresses Pain Hypersensitivity
- (2014) N. Gong et al. JOURNAL OF NEUROSCIENCE
- Neuroprotective and anti-apoptotic effects of liraglutide in the rat brain following focal cerebral ischemia
- (2014) S. Briyal et al. NEUROSCIENCE
- Exendin-4 Reduces Ischemic Brain Injury in Normal and Aged Type 2 Diabetic Mice and Promotes Microglial M2 Polarization
- (2014) Vladimer Darsalia et al. PLoS One
- Design of the liraglutide effect and action in diabetes: Evaluation of cardiovascular outcome results (LEADER) trial
- (2013) Steven P. Marso et al. AMERICAN HEART JOURNAL
- Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice
- (2013) Dong Yang et al. BRAIN RESEARCH
- Neuroprotective Effects of Liraglutide for Stroke Model of Rats
- (2013) Kenichiro Sato et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Exenatide in Acute Ischemic Stroke
- (2013) Samantha C. Daly et al. International Journal of Stroke
- Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
- (2013) Christian Hölscher JOURNAL OF ENDOCRINOLOGY
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride
- (2012) V. Darsalia et al. DIABETES
- Glucagon-Like Peptide-1 Decreases Intracerebral Glucose Content by Activating Hexokinase and Changing Glucose Clearance during Hyperglycemia
- (2012) Michael Gejl et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia
- (2012) Peter Röhnert et al. Journal of Neuroinflammation
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats
- (2011) Seema Briyal et al. BRAIN RESEARCH
- Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats
- (2011) Vladimer Darsalia et al. CLINICAL SCIENCE
- Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
- (2011) Matteo Monami et al. CURRENT MEDICAL RESEARCH AND OPINION
- Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Provides Neuroprotection in Mice Transient Focal Cerebral Ischemia
- (2011) Shinichiro Teramoto et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia
- (2011) Choong Hyun Lee et al. JOURNAL OF NEUROSCIENCE RESEARCH
- Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
- (2010) J. H. Best et al. DIABETES CARE
- Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives
- (2009) Dirk Sander et al. JOURNAL OF NEUROLOGY
- Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system
- (2009) Alison Hamilton et al. NEUROREPORT
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
- (2009) Y. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease
- (2007) Göran Bertilsson et al. JOURNAL OF NEUROSCIENCE RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started